FDNA develops facial dysmorphology novel analysis technology solutions for healthcare professionals. It offers a genetic search and reference tool called Face2Gene that facilitates detection of facial dysmorphic features and recognizable patterns of human malformations from a facial photo to present a list of matching syndromes with up-to-date references. FDNA's solution enables users to upload photos, search and review genetic resources, and analyze results and offers customized reports and visualization tools. Lior Wolf and Moti Shniberg founded it in 2011, with its headquarters in Boston in Massachusetts.

FDNA develops facial dysmorphology novel analysis technology solutions for healthcare professionals. It offers a genetic search and reference tool called Face2Gene that facilitates detection of facial dysmorphic features and recognizable patterns of human malformations from a facial photo to present a list of matching syndromes with up-to-date references. FDNA's solution enables users to upload photos, search and review genetic resources, and analyze results and offers customized reports and visualization tools. Lior Wolf and Moti Shniberg founded it in 2011, with its headquarters in Boston in Massachusetts.

EyeArt is the first and only FDA-cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.It is proven to be safe, fast, and consistent.